Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: determineadequatecellmetastasescells
  Phrases that lowered it: severeeffect ofhepaticmultipledrugs
• Sponsor's past termination rate: 3.8% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 26.4% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 94.1% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 16 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities NCT04037527 · started 2020 · scored riskier than 92% of active trials terminated
• Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy NCT00753688 · started 2008 · scored riskier than 42% of active trials completed
• A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma NCT03809637 · started 2017 · scored riskier than 29% of active trials completed
• NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma NCT03524898 · started 2018 · scored riskier than 61% of active trials terminated
• Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors NCT01407562 · started 2010 · scored riskier than 77% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.